Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer
JAMA Surgery · 2025
DOI: 10.1001/jamasurg.2025.4054 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA Surgery, 2025. Verfasst von Caro L Bruna und 46 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Laparoscopy, Pancreatectomy, Pancreatic Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance The DIPLOMA trial showed comparable radical resection rates after minimally invasive left pancreatectomy (MILP) and open left pancreatectomy (OLP) in patients with upfront resectable pancreatic cancer. Data on long-term overall survival (OS) and disease-free survival (DFS) are currently lacking, but are required before the oncological efficacy of MILP can be confirmed.
Objective
To determine the long-term oncological outcome, including OS and DFS, of MILP vs OLP in patients with upfront resectable left-sided pancreatic cancer in the DIPLOMA trial. Design, Setting, and Participants The randomized, patient-blinded and pathologist-blinded DIPLOMA trial was conducted between 2018 and 2021, with a follow-up duration of at least 36 months. It was a multicenter international trial that took place in 35 centers in 12 countries worldwide. Patients with upfront resectable pancreatic ductal adenocarcinoma of the body or tail of the pancreas were included.
Interventions
Participants were randomly assigned to undergo MILP (laparoscopic and robotic) or OLP. Patients were blinded for the surgical approach. Main Outcomes and Measures Main outcomes included OS and DFS. Other outcomes include receipt of adjuvant therapy and time to start of adjuvant therapy.
Results
Between May 2018 and May 2021, 258 patients were randomized to the MILP (131 patients) and OLP (127 patients) groups. After a median follow-up of 38 (IQR 36-46) months, 134 patients (52%) had died and 127 patients (55%) experienced disease recurrence. OS did not differ significantly between the MILP and OLP groups (median, 32 vs 34 months; stratified hazard ratio, 1.02; 95% CI, 0.72-1.44; P = .92). Also, DFS did not significantly differ between the MILP and OLP groups (median, 21 vs 17 months; stratified hazard ratio, 0.96; 95% CI, 0.68-1.35; P = .81). Adjuvant therapy was administered in 79 patients after MILP (79 of 113 [70%]) and 79 patients after OLP (79 of 110 [72%]) ( P = .63). Time to adjuvant therapy was comparable between groups (median 59 vs 56 days; P = .92). Conclusions and Relevance In this long-term follow-up of the randomized DIPLOMA trial in patients with upfront resectable pancreatic cancer, oncological outcomes after MILP and OLP did not differ significantly, confirming the oncological safety of MILP. Trial Registration International Standard Registered Clinical/Social Study Number Registry Identifier: ISRCTN44897265
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
- Cancer Center Amsterdam, the Netherlands.
- Department of General Surgery, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.
- Department of Surgery, OLVG Hospital, Amsterdam, the Netherlands.
- Department of Pancreatic and Transplant Surgery, San Raffaele Hospital IRCCS, Università Vita-Salute, Milan, Italy.
- Department of Medicine and Technological Innovation (DIMIT), University of Insubria, Ospedale di Circolo, Varese, Italy.
Zitieren
APA
Bruna, C. L., van Hilst, J., Korrel, M., Jones, L. R., Balzano, G., Björnsson, B., Boggi, U., Bratlie, S. O., Busch, O. R., Butturini, G., Capretti, G., Casadei, R., Dokmak, S., Edwin, B., Esposito, A., Falconi, M., Ferrari, G., Hackert, T., Kazemier, G., …, & European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS) (2025). Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer. JAMA Surgery. https://doi.org/10.1001/jamasurg.2025.4054
Vancouver
Bruna CL, van Hilst J, Korrel M, Jones LR, Balzano G, Björnsson B, et al. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer. JAMA Surgery. 2025. doi:10.1001/jamasurg.2025.4054
BibTeX
@article{Bruna2025,
author = {Bruna, Caro L and van Hilst, Jony and Korrel, Maarten and Jones, Leia R and Balzano, Gianpaolo and Björnsson, Bergthor and Boggi, Ugo and Bratlie, Svein Olav and Busch, Olivier R and Butturini, Giovanni and Capretti, Giovanni and Casadei, Riccardo and Dokmak, Safi and Edwin, Bjørn and Esposito, Alessandro and Falconi, Massimo and Ferrari, Giovanni and Hackert, Thilo and Kazemier, Geert and Koerkamp, Bas Groot and de Kleine, Ruben H and Keck, Tobias and Kleive, Dyre B and Kokkola, Arto and Kooby, David and Lips, Daan J and Luyer, Misha D P and Guerra, Martina and Marudanayagam, Ravi and Menon, Krishna and Molenaar, I Quintus and de Pastena, Matteo and Pecorelli, Nicolò and Primrose, John N and Ricci, Claudio and Saint Marc, Olivier and Salvia, Roberto and Sandström, Per and Tomazic, Ales and Wellner, Ulrich F and Yip, Vincent S and Zerbi, Alessandro and Ali, Mahsoem and Dijkgraaf, Marcel G W and Besselink, Marc G and Abu Hilal, Mohammad and European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS), European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS)},
title = {Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer},
journal = {JAMA Surgery},
year = {2025},
doi = {10.1001/jamasurg.2025.4054}
}
EUVIMED